NewTimeSpace News: On 29 August 2026, THREE SQUIRRELS (300783.SZ) announced that its Board had approved the termination of the issuance of H shares and the listing on the Main Board of HKEX, which falls within the scope of authority delegated by the shareholders' meeting and requires no further shareholders' approval; the Company stated that its operations remain normal and the termination will not have a material impact on its business operations and sustainable development.
NewTimeSpace News: The CSRC International Department has published supplementary material requirements for overseas listing filings, requiring Beijing Dynaflow Lab Solutions Co., Ltd. to explain matters including compliance of historical equity changes, entry prices of new shareholders within 12 months before filing, the employee shareholding plan, changes in principal businesses and the background of the Zhongluhangmiao acquisition, and title defects of shares in the "full circulation".
NewTimeSpace News: The CSRC International Department has published supplementary material requirements for overseas listing filings, requiring Shenzhen Everwin Precision Technology Co., Ltd. to explain the business of its offshore subsidiaries and the compliance of overseas investment and foreign exchange registration procedures, as well as the use of proceeds and whether approval procedures for overseas investment have been completed.
NewTimeSpace News: The CSRC International Department has published supplementary material requirements for overseas listing filings, requiring Yangzhou Nanopore Innovative Materials Technology Co., Ltd. to explain matters including compliance of historical equity changes, penetration review of 5%+ shareholders, the employee shareholding plan, overcapacity and "anti-involution" policy alignment, and title defects of shares in the "full circulation".
NewTimeSpace News: The CSRC International Department has published supplementary material requirements for overseas listing filings, requiring Janbon High Tech Co., Ltd. to explain seven matters including red-chip restructuring compliance, controlling shareholder changes, nominee shareholding verification, approval of Middle East investment projects, equity incentive and foreign investment negative list compliance, with clear legal opinions from its counsel.
NewTimeSpace News: On 30 August 2026, Boantong Technologies Limited filed a listing application on the GEM of HKEX; the Company focuses on wireless modules, antennas and PCBA solutions with over 20 years of IoT wireless communications experience, covering consumer, industrial and energy electronics; it offers solutions in over 160 specifications serving more than 1,500 customers annually, with 11.4% year-on-year revenue growth between 2024 and 2025; major customers are located mainly in China, accounting for 89.4%-94.9% of total revenue in the recent two years and two half-year periods.
NewTimeSpace News: On 30 August 2026, Ligent Technologies, Inc. passed the HKEX listing hearing; by 2025 global optical module revenue the Company ranked fifth among professional manufacturers (4.0% share) and third by China optical module revenue (10.1% share); the Company is among the first in China to mass-produce 800G/1.6T optical modules, has developed LPO/LRO optical modules and ELSFP light source modules, and self-develops DFB and EML laser chips; it holds 1,581 patents globally and has participated in the formulation of 61 industry standards.
NewTimeSpace News: On 30 August 2026, Zhejiang Hailiang Co., Ltd. filed a listing application with HKEX; the Company is a global supplier of copper-based products covering HVAC/industrial copper tubes, rods, bars and fittings, ultra-thin copper foil and AIDC liquid cooling components, with 23 production bases in Asia, Europe, North America and Africa as of 31 May 2026; in 2025 the Company ranked first globally in HVAC and industrial copper-processed product shipments and first in copper tube shipments for six consecutive years; 2025 revenue was RMB 83.3 billion, with lithium battery and PCB copper foil revenue up 102.5% year on year and net profit up 61.9% year on year.
NewTimeSpace News: On 30 August 2026, Hangzhou Bangshun Pharmaceutical Co., Ltd. filed a listing application with HKEX; incorporated in 2020, the Company focuses on innovative drugs for oncology and autoimmune diseases, with a pipeline comprising two core products — bezesertinib (a selective JAK2 inhibitor for MF/PV/ET) and CX1440 (a registration-stage BTK inhibitor for ITP/CU/AIHA) — plus five preclinical candidates; according to Frost & Sullivan, bezesertinib is among the first three approved domestic JAK inhibitors for MF in China and ranks first in China for PV and first globally for ET, while CX1440 ranks top three globally for ITP and top two globally for CU and AIHA.
NewTimeSpace News: On 30 August 2026, Beijing XSKY Technology Co., Ltd. filed a listing application with HKEX; by 2025 installations, the Company is China's largest independent distributed AI storage solutions provider with a 10.6% market share, offering data lake and training/inference storage solutions based on proprietary XSEA/XScale technologies, delivered as software or appliances; the Company turned profitable in 2025 with a profit of RMB 7.1 million for the year, recording a profit of RMB 0.3 million in H1 2026 versus a loss of RMB 10.5 million in H1 2025.
NewTimeSpace News: On 28 August 2026, Exegenesis Bio Inc. filed a listing application with HKEX; incorporated in 2019, the Company focuses on gene therapies for neurological and ophthalmic diseases with a pipeline of nine candidates; core product EXG102-031 (wAMD) completed the 52-week follow-up of its Phase IIa trial in China in May 2026 with Phase IIb/III expected in H2 2026, and its US Phase I is complete; core product EXG001-307 (SMA type 1) has completed all Phase I/II trials; key product EXG202 (wAMD/DME/RVO) obtained FDA IND in July 2025 in the US, aiming to bypass Phase I, and NMPA approval in August 2025 in China for a combined Phase I/II study.
NewTimeSpace News: On 28 August 2026, Club Med Lifestyle Group filed a listing application with HKEX; founded in 1950 as the pioneer of the premium all-inclusive resort industry, Club Med operates 69 premium resorts globally with a sales network spanning more than 40 countries and regions across six continents; according to CIC, by 2025 turnover it is the world's largest resort brand and, by number of resorts and turnover, the world's largest all-inclusive resort brand; in 2026 it was included in TIME's 100 Most Influential Companies, the only hotel and resort brand on the list that year.
NewTimeSpace News: On 28 August 2026, Frontera Therapeutics filed a listing application with HKEX; incorporated in 2019, the Company is a clinical-stage gene therapy company focused on ophthalmology and cardiovascular diseases, with a pipeline of six in-house developed rAAV gene therapy candidates, including core products FT-002 (XLRP) and FT-003 (nAMD and DME) and key product FT-001 (RPE65-related IRD); its patent portfolio comprises one Japanese patent and 29 patent applications, with US applications for FT-002 and FT-003 receiving notices of allowance in May and June 2026 respectively.
NewTimeSpace News: On 28 August 2026, Betta Pharmaceuticals Co., Ltd. filed a listing application with HKEX; the Company is a biopharmaceutical company operating across the full industry chain at the commercialization stage, profitable for many consecutive years since its first product launch in 2011; its commercialized products icotinib (Kaima'na, EGFR TKI), ensartinib (Beima'na, ALK TKI) and vorolanib (Fumeina, VEGFR/PDGFR inhibitor) are each the first domestic drug of their class approved in China or entering the global market; the Company has a pipeline of over ten clinical programs covering EGFR, ALK and other targets, also exploring breast cancer, renal cancer, hematological diseases and ophthalmology.
NewTimeSpace News: On 28 August 2026, Hangzhou Tangji Medical Technology Co., Ltd. filed a listing application with HKEX; incorporated in 2016, the Company focuses on the treatment and comprehensive management of metabolic diseases, with core product GBS being China's first medical device approved for the endoscopic treatment of obesity, and is expanding to lower-BMI indications, along with 13 pipeline products; according to Frost & Sullivan, China's obese population reached 233.7 million in 2025 and is expected to reach 329.8 million by 2034, and the China EBMT device market is projected to grow at a CAGR of 111.1% from RMB 32 million in 2025 to RMB 1,352 million in 2030.
NewTimeSpace News: On 28 August 2026, Nanjing Novlead Biotechnology Co., Ltd. re-filed its listing application with HKEX; incorporated in 2018, the Company focuses on inhaled nitric oxide (iNO) therapy, with five approved products (including core product iNOwill, approved by the NMPA in 2022 and CE-certified in 2025) and five candidates in development covering critical care, ward, outpatient and home scenarios; its R&D team of 47 employees represents about 27.5% of total headcount, with H1 2026 R&D expenses of approximately RMB 20.3 million; production facilities are located in Yangzhou, Jiangsu and Fangchenggang, Guangxi.
